Consumer group sues FDA over Aricept safety

by The Associated Press

(AP)—A consumer group pressing the Food and Drug Administration to remove the highest dose of an Alzheimer's disease drug from the market is suing the agency for "foot-dragging."

Public Citizen says the FDA's own reviewers found that high-dose Aricept (AR'ih-sept) doesn't work better than two low doses but has more-dangerous, potentially deadly side effects.

Public Citizen filed a petition in 2011 with the FDA. The group urged the agency to halt sales of the 23-milligram dose of Aricept and put about the high-dose risks on two low doses available under the brand and as generic pills.

The FDA has yet to act. A spokeswoman says FDA doesn't comment on litigation. Last December, the agency wrote to Public Citizen, saying it was doing a review of the case.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA approves larger dose of Pfizer's Aricept

Jul 25, 2010

(AP) -- Drugmakers Eisai Inc. and Pfizer Inc. said on Saturday that government regulators have given them permission to make a larger dose of its Alzheimer's disease drug Aricept for patients who have already been taking ...

Public Citizen wants withdrawal of diabetes drug

Apr 19, 2012

(AP) -- A consumer advocacy group is calling on government regulators to withdraw a diabetes drug from Novo Nordisk, saying the injectable medication raises the risk of thyroid cancer, pancreatitis and kidney failure.

Advocacy group seeks ban on pelvic surgical mesh

Aug 25, 2011

(AP) -- A consumer advocacy group is calling on government regulators to ban a type of surgical mesh used to treat pelvic collapse, saying it exposes patients to serious risks.

Alzheimer's drug sharply criticized by medical experts

Mar 23, 2012

Watching Alzheimer's disease steal away the memory, talents and very selves of its victims is hard enough for the people who love them. But a new pill formulated by a respected pharmaceutical company and approved by the Food ...

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments